Pharma giant GSK posted a first‑quarter core operating profit of 2.65 billion pounds, up from 2.53 billion a year earlier and ahead of the consensus of 2.46 billion. The lift stems mainly from stronger sales of its specialty‑medicine portfolio, which has been a focus of the company’s strategic shift toward high‑margin therapies in the UK and EU markets, boosting shareholder confidence for the fiscal year.

GSK’s management reiterated its 2026 outlook, maintaining guidance that core earnings per share will rise 7%‑9% this year. It also confirmed a total dividend of 70 pence per share for the year, signalling a commitment to returning cash to investors despite the volatile drug‑development cycle. The results reinforce the company’s position as a leading FTSE 100 pharmaceutical player in 2026 globally.

The specialty‑medicine surge reflects GSK’s investment in oncology and rare‑disease drugs, areas that promise higher margins than traditional generics. Analysts note that sustained growth in this segment could lift the company’s market cap beyond current estimates, potentially reshaping investor expectations amid a broader industry shift toward niche biologics. GSK’s performance underscores the strategic value of high‑margin portfolios for 2026 growth.